Home Newsfeeds Morgan Stanley Maintains Equal-Weight on Shopify, Raises Price Target to $42

Morgan Stanley Maintains Equal-Weight on Shopify, Raises Price Target to $42

Morgan Stanley analyst Keith Weiss maintains Shopify (NYSE:SHOP) with a Equal-Weight and raises the price target from $40 to $42.

byBenzinga Newsdesk

October 28, 2022

1 minute read

Morgan Stanley analyst Keith Weiss maintains Shopify (NYSE:SHOP) with a Equal-Weight and raises the price target from $40 to $42.

Aethlon Medical Announces Investigation Of The Hemopurifier For Use In Organ Transplantation

By Happy Mohamed

June 21, 8:07 AM

Research to Confirm the Hemopurifier's Ability to Remove Harmful Viruses and Exosomes From Harvested Organs SAN DIEGO, June 21, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical

AEMD

Hudson Global’s Strong Performance In Q4 Shows Resiliency Of Recruitment Process Outsourcing Model, Analyst Says

By Shivani Kumaresan

March 31, 1:48 PM

EF Hutton analyst Edward Reily reiterated a Buy rating on the shares of Hudson Global Inc (NASDAQ:HSON) with a price target of…

HSON

Elon Musk Is Not Satoshi Nakamoto Because ‘Bitcoin Whitepaper Has No Memes,’ Says DogeDesigner

By Mehab Qureshi

September 4, 8:00 AM

DogeDesigner, as the name suggests, graphic designer at Dogecoin (CRYPTO: DOGE) on Sunday firmly denied the speculation that Elon Musk, the CEO of Tesla and SpaceX, is the elusive creator of Bitcoin (CRYPTO:

$DOGE

Three In A Row: FibroGen’s Investigational Drug Flunks In Another Study For Rare Disease In Young Boys

By Vandana Singh

August 30, 7:42 AM

Tuesday, FibroGen Inc (NASDAQ: FGEN) announced topline data from the Phase 3 LELANTOS-2 trial of pamrevlumab for ambulatory patients with Duchenne muscular dystrophy (DMD) on

FGEN

Morgan Stanley Maintains Equal-Weight on Shopify, Raises Price Target to $42

Related Posts

Aethlon Medical Announces Investigation Of The Hemopurifier For Use In Organ Transplantation

Hudson Global’s Strong Performance In Q4 Shows Resiliency Of Recruitment Process Outsourcing Model, Analyst Says

Elon Musk Is Not Satoshi Nakamoto Because ‘Bitcoin Whitepaper Has No Memes,’ Says DogeDesigner

Three In A Row: FibroGen’s Investigational Drug Flunks In Another Study For Rare Disease In Young Boys